Cargando…
Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672836/ https://www.ncbi.nlm.nih.gov/pubmed/36403700 http://dx.doi.org/10.1016/j.jinf.2022.11.008 |
| _version_ | 1784832828979019776 |
|---|---|
| author | Wang, Guiqiang Zhao, Kexin Han, Jun Hu, Zhongyu Zhang, Tianzuo Wang, Yanchao Shi, Rui Li, Yanhua Song, Qinqin Du, Haijun He, Peng Xu, Shuping Yang, Xinjie Fu, Yongpan Cui, Yimin Xie, Liangzhi |
| author_facet | Wang, Guiqiang Zhao, Kexin Han, Jun Hu, Zhongyu Zhang, Tianzuo Wang, Yanchao Shi, Rui Li, Yanhua Song, Qinqin Du, Haijun He, Peng Xu, Shuping Yang, Xinjie Fu, Yongpan Cui, Yimin Xie, Liangzhi |
| author_sort | Wang, Guiqiang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9672836 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96728362022-11-18 Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial Wang, Guiqiang Zhao, Kexin Han, Jun Hu, Zhongyu Zhang, Tianzuo Wang, Yanchao Shi, Rui Li, Yanhua Song, Qinqin Du, Haijun He, Peng Xu, Shuping Yang, Xinjie Fu, Yongpan Cui, Yimin Xie, Liangzhi J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-11-17 /pmc/articles/PMC9672836/ /pubmed/36403700 http://dx.doi.org/10.1016/j.jinf.2022.11.008 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Wang, Guiqiang Zhao, Kexin Han, Jun Hu, Zhongyu Zhang, Tianzuo Wang, Yanchao Shi, Rui Li, Yanhua Song, Qinqin Du, Haijun He, Peng Xu, Shuping Yang, Xinjie Fu, Yongpan Cui, Yimin Xie, Liangzhi Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial |
| title | Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial |
| title_full | Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial |
| title_fullStr | Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial |
| title_full_unstemmed | Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial |
| title_short | Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial |
| title_sort | safety and immunogenicity of a bivalent sars-cov-2 recombinant protein vaccine, sctv01c in unvaccinated adults: a randomized, double-blinded, placebo-controlled, phase i clinical trial |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672836/ https://www.ncbi.nlm.nih.gov/pubmed/36403700 http://dx.doi.org/10.1016/j.jinf.2022.11.008 |
| work_keys_str_mv | AT wangguiqiang safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT zhaokexin safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT hanjun safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT huzhongyu safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT zhangtianzuo safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT wangyanchao safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT shirui safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT liyanhua safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT songqinqin safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT duhaijun safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT hepeng safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT xushuping safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT yangxinjie safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT fuyongpan safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT cuiyimin safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial AT xieliangzhi safetyandimmunogenicityofabivalentsarscov2recombinantproteinvaccinesctv01cinunvaccinatedadultsarandomizeddoubleblindedplacebocontrolledphaseiclinicaltrial |